B-cell maturation antigen (BCMA) and CD19 antigen are B-cell target antigens frequently used in CAR constructs for autoimmune diseases.1,2 In addition to the B-cell depletion in the peripheral blood, CAR-T cells allow deep depletion of tissue-resident B cells e.g., in lymphoid tissues and hard-to-reach compartments such as the central nervous system (CNS), an effect that has not been observed with antibody-based B-cell depletion therapies. The gene discussed is TNFRSF17; the disease is autoimmune disease.